Clinical Trial

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-06-05; most recent amendment 2026-03-17.
Trial Details
NCT Number NCT03977493
Lead Sponsor Alain Kaelin
Collaborators: Clinical Trial Unit Ente Ospedaliero Cantonale
Conditions Focal Hand Dystonia
Enrollment 48 participants
Start Date 2018-02-21
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-19